1
|
Filbert AL, Kremer L, Ladenstein R, Chronaki C, Degelsegger-Márquez A, van der Pal H, Bardi E, Uyttebroeck A, Langer T, Muraca M, Nieto AC, Rascon J, Bagnasco F, Beyer S, Te Dorsthorst J, Essiaf S, Galan AO, Kienesberger A, O'Brien K, Palau MC, Pluijm SMF, di Profio S, Saraceno D, Schneider C, Schreier G, Trinkūnas J, Zamberlan I, Grabow D, Haupt R. Scaling up and implementing the digital Survivorship Passport tool in routine clinical care - The European multidisciplinary PanCareSurPass project. Eur J Cancer 2024; 202:114029. [PMID: 38513384 DOI: 10.1016/j.ejca.2024.114029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 03/11/2024] [Accepted: 03/14/2024] [Indexed: 03/23/2024]
Abstract
BACKGROUND Childhood cancer survivors (CCS), of whom there are about 500,000 living in Europe, are at an increased risk of developing health problems [1-6] and require lifelong Survivorship Care. There are information and knowledge gaps among CCS and healthcare providers (HCPs) about requirements for Survivorship Care [7-9] that can be addressed by the Survivorship Passport (SurPass), a digital tool providing CCS and HCPs with a comprehensive summary of past treatment and tailored recommendations for Survivorship Care. The potential of the SurPass to improve person-centred Survivorship Care has been demonstrated previously [10,11]. METHODS The EU-funded PanCareSurPass project will develop an updated version (v2.0) of the SurPass allowing for semi-automated data entry and implement it in six European countries (Austria, Belgium, Germany, Italy, Lithuania and Spain), representative of three infrastructure healthcare scenarios typically found in Europe. The implementation study will investigate the impact on person-centred care, as well as costs and processes of scaling up the SurPass. Interoperability between electronic health record systems and SurPass v2.0 will be addressed using the Health Level Seven (HL7) International interoperability standards. RESULTS PanCareSurPass will deliver an interoperable digital SurPass with comprehensive evidence on person-centred outcomes, technical feasibility and health economics impacts. An Implementation Toolkit will be developed and freely shared to promote and support the future implementation of SurPass across Europe. CONCLUSIONS PanCareSurPass is a novel European collaboration that will improve person-centred Survivorship Care for CCS across Europe through a robust assessment of the implementation of SurPass v2.0 in different healthcare settings.
Collapse
Affiliation(s)
- Anna-Liesa Filbert
- Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Leontien Kremer
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Ruth Ladenstein
- St. Anna Children's Cancer Research Institute, Vienna, Austria; St Anna Children's Hospital, Vienna, Austria
| | | | | | | | - Edit Bardi
- St Anna Children's Hospital, Vienna, Austria; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria
| | | | - Thorsten Langer
- Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Germany
| | | | | | - Jelena Rascon
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Clinics for Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania
| | | | - Stefan Beyer
- AIT Austrian Institute of Technology, Graz, Austria
| | | | | | | | | | | | | | - Saskia M F Pluijm
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Sonia di Profio
- Clinical Psychology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | | | | | | | - Justas Trinkūnas
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | | | - Desiree Grabow
- Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
| | | |
Collapse
|
2
|
Baumgartner M, Grössl M, Haumer R, Poimer K, Prantl F, Weick K, Falgenhauer M, Beyer S, Ziegl A, Lauschensky A, Wiesmüller F, Kreiner K, Hayn D, Schreier G. Neural Network-Based Prediction of Perceived Sleep Quality Through Wearable Device Data. Stud Health Technol Inform 2024; 313:221-227. [PMID: 38682534 DOI: 10.3233/shti240041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2024]
Abstract
BACKGROUND This study focuses on the development of a neural network model to predict perceived sleep quality using data from wearable devices. We collected various physiological metrics from 18 participants over four weeks, including heart rate, physical activity, and both device-measured and self-reported sleep quality. OBJECTIVES The primary objective was to correlate wearable device data with subjective sleep quality perceptions. METHODS Our approach used data processing, feature engineering, and optimizing a Multi-Layer Perceptron classifier. RESULTS Despite comprehensive data analysis and model experimentation, the predictive accuracy for perceived sleep quality was moderate (59%), highlighting the complexities in accurately quantifying subjective sleep experiences through wearable data. Applying a tolerance of 1 grade (on a scale from 1-5), increased accuracy to 92%. DISCUSSION More in-depth analysis is required to fully comprehend how wearables and artificial intelligence might assist in understanding sleep behavior.
Collapse
Affiliation(s)
- Martin Baumgartner
- AIT Austrian Institute of Technology, Graz & Vienna, Austria
- Institute of Neural Engineering, Graz University of Technology, Graz, Austria
| | - Manuel Grössl
- University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria
| | - Raphaela Haumer
- University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria
| | - Katharina Poimer
- University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria
| | - Flora Prantl
- University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria
| | - Katharina Weick
- University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria
| | | | - Stefan Beyer
- AIT Austrian Institute of Technology, Graz & Vienna, Austria
| | - Andreas Ziegl
- telbiomed Medizintechnik und IT Service GmbH, Graz, Austria
| | | | - Fabian Wiesmüller
- AIT Austrian Institute of Technology, Graz & Vienna, Austria
- Institute of Neural Engineering, Graz University of Technology, Graz, Austria
- Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria
| | - Karl Kreiner
- AIT Austrian Institute of Technology, Graz & Vienna, Austria
| | - Dieter Hayn
- AIT Austrian Institute of Technology, Graz & Vienna, Austria
- Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria
| | - Günter Schreier
- AIT Austrian Institute of Technology, Graz & Vienna, Austria
- Institute of Neural Engineering, Graz University of Technology, Graz, Austria
| |
Collapse
|
3
|
Falgenhauer M, Lauschensky A, Kreiner K, Beyer S, Reiter K, Ziegl A, Modre-Osprian R, Pfeifer B, Neururer S, Krestan S, Wagner H, Huber A, Plaikner S, Kuppelwieser S, Widschwendter M, Schreier G. Towards an Electronic Health Prevention Record Based on HL7 FHIR and the OMOP Common Data Model. Stud Health Technol Inform 2024; 313:107-112. [PMID: 38682513 DOI: 10.3233/shti240020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2024]
Abstract
BACKGROUND Approximately 40% of all recorded deaths in Austria are due to behavioral risks. These risks could be avoided with appropriate measures. OBJECTIVES Extension of the concept of EHR and EMR to an electronic prevention record, focusing on primary and secondary prevention. METHODS The concept of a structured prevention pathway, based on the principles of P4 Medicine, was developed for a multidisciplinary prevention network. An IT infrastructure based on HL7 FHIR and the OHDSI OMOP common data model was designed. RESULTS An IT solution supporting a structured and modular prevention pathway was conceptualized. It contained a personalized management of prevention, risk assessment, diagnostic and preventive measures supported by a modular, interoperable IT infrastructure including a health app, prevention record web-service, decision support modules and a smart prevention registry, separating primary and secondary use of data. CONCLUSION A concept was created on how an electronic health prevention record based on HL7 FHIR and the OMOP common data model can be implemented.
Collapse
Affiliation(s)
| | | | - Karl Kreiner
- AIT Austrian Institute of Technology GmbH, Graz, Austria
| | - Stefan Beyer
- AIT Austrian Institute of Technology GmbH, Graz, Austria
| | | | - Andreas Ziegl
- AIT Austrian Institute of Technology GmbH, Graz, Austria
- telbiomed Medizintechnik und IT Service GmbH, Graz, Austria
| | | | - Bernhard Pfeifer
- Tyrolean Federal Institute for Integrated Care, Tirol Kliniken, Innsbruck, Austria
- Division for Digital Health and Telemedicine, UMIT TIROL - Private University for Health Sciences and Health Technology, Hall (Tyrol), Austria
| | - Sabrina Neururer
- Tyrolean Federal Institute for Integrated Care, Tirol Kliniken, Innsbruck, Austria
- Division for Digital Health and Telemedicine, UMIT TIROL - Private University for Health Sciences and Health Technology, Hall (Tyrol), Austria
| | - Susanne Krestan
- Tyrolean Federal Institute for Integrated Care, Tirol Kliniken, Innsbruck, Austria
| | - Hanna Wagner
- Tyrolean Federal Institute for Integrated Care, Tirol Kliniken, Innsbruck, Austria
| | - Andreas Huber
- Tyrolean Federal Institute for Integrated Care, Tirol Kliniken, Innsbruck, Austria
| | - Sandra Plaikner
- EUTOPS Institute, University of Innsbruck, Innsbruck, Austria
| | - Sarah Kuppelwieser
- EUTOPS Institute, University of Innsbruck, Innsbruck, Austria
- Tirol Kliniken GmbH, Innsbruck, Austria
| | - Martin Widschwendter
- EUTOPS Institute, University of Innsbruck, Innsbruck, Austria
- Tirol Kliniken GmbH, Innsbruck, Austria
| | | |
Collapse
|
4
|
Topalov NE, Mayr D, Kuhn C, Leutbecher A, Scherer C, Kraus FBT, Tauber CV, Beyer S, Meister S, Hester A, Kolben T, Burges A, Mahner S, Trillsch F, Kessler M, Jeschke U, Czogalla B. Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer. Sci Rep 2023; 13:22620. [PMID: 38114558 PMCID: PMC10730610 DOI: 10.1038/s41598-023-49286-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Accepted: 12/06/2023] [Indexed: 12/21/2023] Open
Abstract
Actin beta-like 2 (ACTBL2) was recently identified as a new mediator of migration in ovarian cancer cells. Yet, its impact on tumor-infiltrating and thus migrating leukocytes (TILs) remains to date unknown. This study characterizes the subset of ACTBL2-expressing TILs in epithelial ovarian cancer (EOC) and elucidates their prognostic influence on the overall survival of EOC patients with special regard to different histological subtypes. Comprehensive immunohistochemical analyses of Tissue-Microarrays of 156 ovarian cancer patients revealed, that a tumor infiltration by ACTBL2-positive leukocytes was significantly associated with an improved overall survival (OS) (61.2 vs. 34.4 months; p = 0.006) and was identified as an independent prognostic factor (HR = 0.556; p = 0.038). This significant survival benefit was particularly evident in patients with low-grade serous carcinoma (OS: median not reached vs. 15.6 months, p < 0.001; HR = 0.058, p = 0.018). In the present cohort, ACTBL2-positive TILs were mainly composed of CD44-positive cytotoxic T-cells (CD8+) and macrophages (CD68+), as depicted by double-immunofluorescence and various immunohistochemical serial staining. Our results provide significant evidence of the prognostic impact and cellular composition of ACTBL2-expressing TILs in EOC. Complementary studies are required to analyze the underlying molecular mechanisms of ACTBL2 as a marker for activated migrating leukocytes and to further characterize its immunological impact on ovarian carcinogenesis.
Collapse
Affiliation(s)
- N E Topalov
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
| | - D Mayr
- Institute of Pathology, Faculty of Medicine, University Hospital, LMU Munich, Munich, Germany
| | - C Kuhn
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - A Leutbecher
- Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - C Scherer
- Department of Medicine I, University Hospital, LMU Munich, Munich, Germany
| | - F B T Kraus
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - C V Tauber
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - A Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - T Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - A Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - F Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - M Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - U Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - B Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
5
|
Upadhyay R, Elguindy AN, Sengupta S, Wang K, Beyer S, Thomas EM, Raval R, Palmer JD. Initial Report of Boswellia Serrata for Management of Cerebral Radiation Necrosis after Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys 2023; 117:S172-S173. [PMID: 37784429 DOI: 10.1016/j.ijrobp.2023.06.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Radiation necrosis (RN) is a concerning late toxicity after radiation therapy (RT) for brain metastases. Oral corticosteroids are the mainstay of management; however, they are not optimal for long-term use given multiple side effects and drug interactions, particularly with the emergence of immunotherapy for several cancers. Boswellia serrata (BS) is an over-the-counter supplement used for its anti-inflammatory properties and has been recently shown to reduce cerebral edema after brain RT. We evaluated the response rates with BS in a series of patients with brain metastases treated with stereotactic radiosurgery (SRS) who developed RN. MATERIALS/METHODS We included patients who developed RN after SRS for brain metastases at our institution from 2020-2022 and were treated with BS. Patients were prescribed over the counter BS 4.2-4.5g daily in divided doses. Follow-up MRI imaging was obtained every 2-3 months after starting BS. Response was assessed using Response Assessment in Neuro-Oncology (RANO) criteria. Primary endpoint was ≥25% decrease in edema volume on T2-FLAIR MRI from baseline. Patients were censored if they had tumor progression or repeat RT to necrotic area, or death. Kaplan-Meier curves were used for survival estimates. RESULTS A total of 50 patients received BS for Grade 1-3 CTCAE v5.0 RN (G1 = 11, G2 = 36, and G3 = 3). Median age was 62.8 years (range 36.9 - 50) and median RT dose was 24 Gy in 3 fractions. Median time to RN after SRS was 10 months(m). Median follow-up after starting BS was 6m and 40 patients had at least 1 follow up MRI available to evaluate response. The best response was complete response (CR) in 15% patients and partial response (PR) in 40% while 35% had stable disease (SD) and 10% had progressive disease. Median time to CR was 9m (6-12m) and PR was 6m (3-12m). Percentage of patients who had any response (CR or PR) at 3, 6, 9 and 12 months was 25%, 60%, 43% and 50%, respectively. 56% patients had symptomatic RN, of which 35.7% had improvement in symptoms with BS alone, while 64% required steroid use. Overall, median duration of response in patients with CR, PR or SD was 7.5m(range 2-31m). Salvage treatment for RN was steroids (33), surgery (4), Bevacizumab (5) or hyperbaric oxygen therapy (1). No patients had any CTCAE grade 3 or higher toxicities. 3 patients (6%) had any side-effects all of whom had Grade 1-2 gastrointestinal intolerance or diarrhea. 2 patients stopped treatment due to enrolment on an immunotherapy clinical trial. Overall, 39 patients remained on BS at last follow-up or death. CONCLUSION We observed >50% response rates with use of BS in our cohort of patients with Grade 1-3 RN after SRS. More than 1/3rd patients with symptomatic RN were able to avoid long-term steroid use. BS is an easily available over-the-counter drug that appears to be a safe and promising treatment option for RN, and can potentially decrease steroid dependence in these patients, reducing the risk of several side-effects. Further prospective studies to compare Boswellia with placebo is warranted.
Collapse
Affiliation(s)
| | - A N Elguindy
- The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - S Sengupta
- Department of Neurology, University of Cincinnati, Cincinnati, OH
| | - K Wang
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
6
|
Dohm AE, Upadhyay R, Tang JD, Oliver DE, Perez BA, Rosenberg SA, Yu HHM, Palmer JD, Beyer S, Owen D, Ahmed KA. Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series. Int J Radiat Oncol Biol Phys 2023; 117:e100-e101. [PMID: 37784626 DOI: 10.1016/j.ijrobp.2023.06.869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Given the increased brain penetrance of osimertinib, the role of upfront radiotherapy (RT) has been questioned for the management of patients with EGFR+ NSCLC brain metastases (BM). We conducted a multi-institutional review of patients with EGFR+ NSCLC treated with upfront osimertinib or osimertinib in combination with RT for new or progressing BM. MATERIALS/METHODS Our multi-institutional analysis included 128 patients with 714 BM treated between 2013 and 2022. Two BM treatment groups were evaluated: (1) upfront osimertinib alone (n = 66) and (2) osimertinib + RT [whole brain radiation therapy or stereotactic/fractionated radiosurgery (SRS/FSRT)] prior or concurrently with osimertinib (n = 62)]; both groups began treatment within 2 months of BM diagnosis. Time-to-event analysis was conducted with the Kaplan-Meier (KM) method, and outcomes included intracranial control (IC) [both local and distant], intracranial progression free survival (IPFS), and overall survival (OS). A Cox proportional hazards model was utilized for multivariate analysis (MVA). RESULTS Median follow-up from BM diagnosis was 33.9 months (0.13-76.2 months). No differences in age (p = 0.46), sex (p = 0.72), DS-GPA (p = 0.08), KPS (p = 0.57), number of BM (p = 0.19) or volume of BM (p = 0.45), RT dose (p = 0.45), number of systemic metastases (p = 0.88), and patients symptomatic at presentation (p = 1.0) were noted. Prior treatment of BM was more common in the osimertinib + RT group (50% osimertinib + RT and 27% osimertinib; p = 0.01). The 12-month KM rates for osimertinib vs osimertinib + RT groups for IC were 72% vs 73% (p = 0.33); IPFS 53% vs 66% (p = 0.007); and OS 65% vs 80% (p = 0.025). On MVA, higher KPS (p = 0.002) was associated with increased OS and no extracranial metastasis with increased OS (p = 0.01) and IPFS (p = 0.001). MVA showed no association between osimertinib vs osimertinib + RT for IC, IPFS, or OS. Of the 66 patients treated with upfront osimertinib, 18 patients (27%) with 31 lesions eventually required RT for intracranial progression with the majority 72% being treated with SRS/FSRT at median of 13.5 months (1-22 months) following the start of osimertinib. CONCLUSION This study suggests that upfront osimertinib alone may provide sufficient intracranial control to allow RT to be deferred until further intracranial progression in select patients. Prospective trials are warranted to further guide treatment.
Collapse
Affiliation(s)
- A E Dohm
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - R Upadhyay
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Tang
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - D E Oliver
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - B A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - S A Rosenberg
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - H H M Yu
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D Owen
- The Ohio State University, Columbus, OH
| | - K A Ahmed
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| |
Collapse
|
7
|
McCalla A, Upadhyay R, Perlow HK, Raval R, Beyer S, Blakaj DM, Grecula JC, Palmer JD, Thomas EM. WBRT is Associated with Higher Rates of Hematologic Toxicity than Stereotactic Radiosurgery in Brain Metastasis Patients. Int J Radiat Oncol Biol Phys 2023; 117:e137-e138. [PMID: 37784705 DOI: 10.1016/j.ijrobp.2023.06.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Whole brain radiotherapy (WBRT) has historically been a standard of care in patients with multiple brain metastases. Studies show that WBRT may be associated with a transient detriment in hematological parameters because of exposure to a larger proportion of circulating lymphocytes, platelets and hematopoietic cells within the bone marrow of the cranium. In this study, we tested the hypothesis that stereotactic radiotherapy (SRS) may cause reduced hematologic toxicity in patients compared to WBRT. MATERIALS/METHODS We retrospectively identified 100 patients treated for brain metastasis, with either SRS or WBRT from 2016 to 2019, and queried their pre- and post-treatment hematological parameters including hemoglobin, total white blood cell (WBC), absolute neutrophil count (ANC), absolute lymphocyte count, and platelet count. CTCAE v5.0 was used for grading hematologic toxicities. Serial values were compared by treatment type and controlled for age, gender, and systemic therapy. Student t-test was used for intergroup comparison and p-value <0.05 was considered significant. RESULTS Of 100 patients, median brain metastases was 3 (range 1-22), 51 received SRS and 49 received WBRT. We observed that patients treated with WBRT had a significantly higher post-treatment reduction in platelet count (-51.2 vs 9.8; p = 0.001) and higher incidence of any grade thrombocytopenia (31.2% vs 10%; p = 0.019) compared to patients treated with SRS. We also noted that compared with SRS, WBRT was associated with a higher post-treatment reduction in circulating lymphocytes (-0.80 vs 0.14; p = 0.071) and higher incidence of G3+ lymphopenia (43.2% vs 22.2%; p = 0.07). Numerical incidence of any G3+ hematological toxicity was also higher in the WBRT group but the difference was not statistically significant (40% vs 28%, p = 0.162). Hemoglobin count, WBC, and ANC were not meaningfully different pre- and post-treatment for either group. CONCLUSION WBRT results in an increased amount and duration of radiation exposure to circulating intracranial blood volume. In our study, patients treated with WBRT experienced higher rates of clinically significant lymphopenia & thrombocytopenia compared to patients treated with SRS. In addition to the cognitive benefits of SRS compared to WBRT, there may be significant hematologic benefits as well. Further studies are warranted to clarify and validate these findings.
Collapse
Affiliation(s)
- A McCalla
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | | | - H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D M Blakaj
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
8
|
Perlow HK, Matsui JK, Ewing A, Cadieux C, Blakaj DM, Beyer S, Thomas EM, Grecula JC, Raval R, Palmer JD. Volumetric Modulated Arc Therapy Craniospinal Irradiation Utilizing a Vertebral Body Sparing Approach: A Toxicity Analysis. Int J Radiat Oncol Biol Phys 2023; 117:S174. [PMID: 37784434 DOI: 10.1016/j.ijrobp.2023.06.642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Craniospinal irradiation (CSI) is indicated for adult patients diagnosed with leptomeningeal disease (LMD). Proton-based vertebral-body-sparing (VBS) CSI has been explored with pediatric patients to minimize hematologic toxicity; however, utilization of VBS in an adult population is limited. A recent phase II trial (Yang et al, JCO 2022) has shown efficacy of proton-based CSI to treat non-small cell lung and breast cancer with LMD. We hypothesize that VBS-CSI utilizing volumetric modulated arc therapy (VMAT) could also effectively reduce dose to vertebral bodies and surrounding organs-at-risk (OARs), minimizing toxicity for adult patients with LMD and comparing favorably to proton-based CSI. MATERIALS/METHODS Consecutive patients with leptomeningeal disease received VMAT VBS-CSI, 30 Gy in 10 fractions, as a part of a prospective registry. Full VMAT arcs for the brain fields matched to two spine isocenters for the upper and lower spine were created utilizing limited posterior arcs. The PTV was created with margins of 3mm uniformly around the brain contour and 7mm around the spinal canal. To further decrease the vertebral body dose, an avoid entry and exit contour was created. This structure was a margin on the PTV anteriorly designed to carve dose out of the vertebral bodies while still maintaining coverage to the PTV. Acute toxicity data were collected using Common Terminology Criteria for Adverse Events (CTCAE) v5 and was defined as toxicity occurring within 30 days of treatment conclusion. RESULTS Ten adult patients were treated in this cohort. All patients completed radiation treatment. One patient experienced Grade 2 neutropenia with the remaining nine experiencing Grade 1 hematologic toxicity (three Grade 1 pancytopenia, six Grade 1 thrombocytopenia). Three patients experienced Grade 2 gastrointestinal toxicity (Grade 2 nausea, Grade 2 esophagitis, Grade 2 esophagitis/Grade 2 diverticulitis) with the remaining seven experiencing Grade 1 nausea. No patient experienced Grade 3+ toxicities in this cohort. One patient experienced a 5-day delay in systemic therapy initiation due to neutropenia; otherwise, all patients planned for systemic therapy started without delay. CONCLUSION VMAT VBS-CSI is an effective technique to reduce dose to surrounding OARs and vertebral bodies. In this study, VMAT VBS-CSI led to acceptable toxicity compared to patients treated with proton CSI on a phase 2 clinical trial. An NRG phase 3 clinical trial may be developed to evaluate the efficacy of proton-based CSI for patients with LMD. However, these data show how VMAT VBS-CSI may be an acceptable alternative for centers without proton therapy capabilities. Given its promising early results, future prospective evaluation of the technique is warranted.
Collapse
Affiliation(s)
- H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J K Matsui
- The Ohio State University College of Medicine, Columbus, OH
| | - A Ewing
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - C Cadieux
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D M Blakaj
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
9
|
Upadhyay R, Palmer JD, Perlow HK, Schoenhals J, Ghose J, Rajappa P, Blakaj DM, Beyer S, Grecula JC, Sim AJ, Hardesty D, Elder JB, Chakravarti A, Thomas EM, Raval R. Patient-Reported Cognitive Outcomes and Survival after Stereotactic Radiosurgery for 15 or More Brain Metastases. Int J Radiat Oncol Biol Phys 2023; 117:e153-e154. [PMID: 37784741 DOI: 10.1016/j.ijrobp.2023.06.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Overall survival (OS) in metastatic cancer patients has been improving with continued advancements, necessitating greater attention to treatment related toxicities. Patients with ≥ 15 brain metastases (BM) continue to be treated with whole brain radiation therapy (WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery (SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics. MATERIALS/METHODS Patients who received SRS for ≥ 15 BMs in 1-5 fractions from 2014-2022 using the previously described single isocenter multi-target technique were included. Cognitive outcomes were objectively evaluated using serial Patient-Reported Outcome Measurement Information System (PROMIS) scores. Kaplan-Meier method was used for survival analysis and log-rank test was used for intergroup comparisons. RESULTS A total of 118 patients underwent 124 courses of LINAC-based SRS. The mean and median number of lesions treated per patient was 24.8 and 20, respectively (range 15 - 94). Most common primary histologies were lung (47.6%), melanoma (21.0%), and breast (14.5%). The median SRS dose was 24 Gy (range 18 - 30 Gy) with 87.9% receiving 3 fraction SRS. At the time of SRS, 19.4% patients had received prior WBRT and 24.2% had received at least one prior SRS course. The rate of any grade radiation necrosis (RN) and ≥ grade 3 RN were 15.3% and 3.2% respectively. New onset seizures were seen in 2.4%, alopecia in 2.4%, and subjective cognitive decline in 4% of patients. Median follow-up by reverse Kaplan-Meier method was 17.8 months (m). Cognitive data was available for 38 patients. Mean PROMIS scores at baseline, 3m, 6m and 9m after SRS were 32.0, 31.6, 30.4 and 28.7 out of 40, respectively. When longitudinal trends were available, 25 of 31 patients had a stable or improved PROMIS score. The 12m local control was 97.6%. Cumulative incidence of distant intracranial failure was 79.2%. One year freedom from neurological death, leptomeningeal disease, and salvage WBRT were 85.6%, 87.6% and 71.7% respectively. Median OS from brain metastases diagnosis was 11.3m (95% CI 7.2m - 15.3m) overall, while it was 9.2m (6.5 - 11.8m) after excluding patients who had prior WBRT or SRS (n = 79). One-year survival was 40% from diagnosis and 38.7% from SRS. On Cox regression analysis, prior WBRT (p = 0.002), higher KPS (p = 0.050), systemic therapy after SRS (p<0.001), and controlled extracranial disease (p = 0.007) predicted for improved OS. CONCLUSION We present here the largest study evaluating SRS for patients with ≥ 15 BMs. We found that SRS was safe, had favorable cognitive outcomes, and comparable survival outcomes to contemporary studies evaluating WBRT in this patient population. Treatment-naïve patients had a median survival of > 6 months, long enough to benefit from cognitive sparing with SRS. Our study supports further randomized studies comparing SRS and memory avoidance WBRT approaches for patients with ≥ 15 BMs.
Collapse
Affiliation(s)
- R Upadhyay
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J Schoenhals
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J Ghose
- The Ohio State University, Columbus, OH
| | - P Rajappa
- Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH
| | - D M Blakaj
- James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A J Sim
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - D Hardesty
- Department of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J B Elder
- The James Cancer Hospital, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
10
|
Perlow HK, Nalin A, Ritter A, Addington M, Ward A, Liu M, Nappi C, Blakaj DM, Beyer S, Thomas EM, Grecula JC, Raval R, Kotecha R, Boulter D, Dawson E, Zoller W, Palmer JD. Advancing beyond the Hippocampus to Preserve Cognition for Patients with Brain Metastases: Dosimetric Results from a Phase 2 Trial of Memory-Avoidance Whole Brain Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e145-e146. [PMID: 37784722 DOI: 10.1016/j.ijrobp.2023.06.960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Recent advances to preserve neurocognitive function in patients treated for brain metastases include stereotactic radiosurgery (SRS), hippocampal avoidance whole brain radiation therapy (HA-WBRT), and memantine administration. However, 23% of patients receiving HA-WBRT and memantine on NRG-CC001 still experienced executive function deterioration at 4 months, with 12% experiencing total recall and delayed recognition deterioration at 6 months. The hippocampus, corpus callosum, fornix, and amygdala are key neurocognitive substructures with a low propensity for brain metastases. Herein, we report our preliminary experience using an advanced "memory-avoidance" WBRT (MA-WBRT) approach sparing these substructures for patients with multiple (>15) brain metastases. MATERIALS/METHODS Ten consecutive patients treated with MA-WBRT on a phase 2 clinical trial (OSU-21074) were reviewed. In each patient, the hippocampi, amygdalae, corpus callosa, and fornix were contoured. Patients were not eligible for MA-WBRT if they had metastases in these substructures. A memory- avoidance region created using a 5mm volumetric expansion around these substructures. Hotspots were avoided in the hypothalamus and pituitary gland. Dose constraints for these avoidance structures were modeled after NRG CC-001 and include a D100% ≤ 9 Gy and a D0.03 cc ≤ 16 (acceptable to 20 Gy). Coverage of brain metastases was prioritized over memory avoidance dose constraints. Linac-based volumetric modulated arc therapy (VMAT) plans were generated for a prescription dose of 30 Gy in 10 fractions. RESULTS On average, the memory avoidance structure volume was 37.1 ccs (Range: 25.2-44.6 ccs), occupying 2.5% of the entire whole brain target volume. All treatment plans met the D100% dose constraint, and 8/10 plans met the D0.03cc constraint, with priority given to tumor coverage for the remaining 2 cases. VMAT spared the memory avoidance structures with a median dose range of 10.8-14.2 Gy and a maximum dose (D0.03cc) range of 15.6-22.7 Gy. The mean dose to the memory avoidance structures was 12.7 Gy (Range: 11.5-13.8 Gy). Target coverage (D98% > 25 Gy) and homogeneity (D2% ≤ 37.5 Gy) were achieved for all plans. CONCLUSION Modern VMAT techniques allow for sparing of the hippocampus, amygdala, corpus callosum, and fornix with good target coverage and homogeneity. Prospective quality of life and cognitive data including are being collected and include the Functional Assessment of Cancer Therapy - Brain (Fact-Br), Hopkins Verbal Learning Test (HLVT-R), Trail Making Test A/B (TMT-A/B) and Controlled Oral Word Association Test (COWAT). After enrollment is completed, these data will be evaluated to assess the efficacy of MA-WBRT to mitigate declines in quality of life and cognition after whole brain radiation.
Collapse
Affiliation(s)
- H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A Nalin
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A Ritter
- The Ohio State University, Columbus, OH
| | - M Addington
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A Ward
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - M Liu
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - C Nappi
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D M Blakaj
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Kotecha
- Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - D Boulter
- Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E Dawson
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - W Zoller
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
11
|
Dibs K, Facer BD, Palmer JD, Pan J, Raval R, Thomas EM, Cochran ER, Beyer S, Grecula JC, Ayan AS, Zoller W, Christ D, Scharschmidt T, Elder JB, Bourekas E, Xu D, Chakravarthy V, Elguindy AN, Chakravarti A, Blakaj DM. Vertebral Compression Fracture Post Spine Stereotactic Body Radiotherapy: The Role of Vertebral Endplate. Int J Radiat Oncol Biol Phys 2023; 117:e99. [PMID: 37786229 DOI: 10.1016/j.ijrobp.2023.06.866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Maintaining hydrostatic pressure -via Pascal's Principle- between vertebral bodies is essential to decrease the chance of vertebral compression fracture (VCF). Vertebral endplates (EP) play an essential role in this matter through maintaining the mechanical environment as well as the proper nutrition of avascular discs. The purpose of this study is to establish the correlation of VCF with disrupted EP by tumor involvement. MATERIALS/METHODS A retrospective analysis of de novo spine metastases treated with stereotactic body radiotherapy (SBRT) between 2013-2019. Patients (pts) with previous surgical intervention were excluded. VCF defined as new or progression of existing loss of vertebral body height. The vertebral EP region defined in relation to the vertebral body as superior EP vs inferior EP. Kaplan-Meier curves used to analyze the variables. A multivariate proportional hazard model used to assess the risk of all covariates. RESULTS A total of 111 pts were treated with SBRT with a median dose of 27 Gy (10-35 Gy). Median follow-up was 18 months (1.2-107). The median age was 60 years (24-87) and 59 were males (53%) and 52 were females (47%). The median body mass index (BMI) was 27 kg/m2 (16-47). Almost 9 pts diagnosed with osteoporosis prior radiation. Twelve pts received prolonged steroids. Twenty pts received bisphosphonate and 8 pts received denosumab. The median PTV was 50cc (8-465) and median Conformity Index was 1.05 (0.42-1.4). Almost 75% of pts received >95% of the dose covering 100% of the PTV. The most common histopathologies were renal cell carcinoma (25%), lung (13%) and breast (11%). Most of the pts (77%) had SINS score of 7 or less. 48 pts (43%) had either superior or inferior EP disruption secondary to the tumor at the time of radiation. Twenty pts (18%) had both superiorly and inferiorly disrupted EP. Around 20 pts (18%) developed VCF. The median time to VCF was 5.2 months (1.1-57.4). The one-year cumulative incidence of VCF was 18%. The 1-year cumulative incidence of VCF with either superiorly and/or inferiorly disrupted EP was 29% vs 6%, p value <0.001. The 1-year cumulative incidence of VCF with both superiorly and inferiorly disrupted EP was 57% vs 7% (p value <0.001). The median time to VCF was earlier in pts with both disrupted EP (2.4 months vs 5.7 months, p value <0.05). Other risk factors like SINS score of >7 and local recurrence (LR) associated with higher risk of VCF. On multivariate analysis, LR (HR 8.2 [CI 2.4-28, p- value <0.001]), tumor disrupting the EP (HR 4.5 [CI 1.3-16, p-value<0.018]) and SINS score of seven and above (HR 1.7 [CI 1.3-2.25, p-value <0.001]) correlated with the VCF risk. CONCLUSION In this retrospective analysis, tumor disrupting the EP, disease recurrence and high SINS score increased the risk of VCF. Cement augmentation either prophylactically or immediately following SBRT is currently being studied in a prospective trial within our institution.
Collapse
Affiliation(s)
- K Dibs
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - B D Facer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J Pan
- The Ohio State University Wexner Medical Center, Center for Biostatistics, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E R Cochran
- The Ohio State University Hospital, Columbus, OH, United States
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A S Ayan
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - W Zoller
- The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - D Christ
- The Ohio State University Wexner Medical Center, Department of Radiation Oncology, Columbus, OH
| | | | - J B Elder
- The James Cancer Hospital, Columbus, OH
| | - E Bourekas
- The Ohio State University Wexner Medical Center, Department of Neuroradiology, Columbus, OH
| | - D Xu
- Department of neurosurgery, The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - V Chakravarthy
- Department of neurosurgery, The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - A N Elguindy
- The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - D M Blakaj
- James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
| |
Collapse
|
12
|
Kumar A, Rajasekera P, Becker V, Biehn S, Pérez-Soto B, Beyer S, McElroy J, Becker A, Johnson B, Cui T, Sebastian E, Grosu A, Lindert S, Bell EH, Manring H, Haque J, Chakravarti A. Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3β Pathway in Glioblastoma. Int J Radiat Oncol Biol Phys 2023; 117:e121. [PMID: 37784671 DOI: 10.1016/j.ijrobp.2023.06.910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Glioblastoma (GBM) patients with wild-type IDH experience worse survival response to the standard treatment of surgery followed by radiation therapy (RT) and temozolomide (TMZ) chemotherapy compared to their mutant IDH counterparts. This treatment has remained relatively ineffective partly due to the highly invasive phenotype of GBM leading to therapeutic resistance and tumor recurrence. Hypoxia is one of the key characteristic features of GBM which results in cancer metastasis and confers treatment resistance. Therefore, it is paramount to identify targets to help overcome hypoxia-induced treatment resistance in glioblastoma. Our lab has identified transgelin-2 (TAGLN2) to be significantly upregulated in IDH-wt GBM through multiple molecular profiling studies. This study aims to understand the mechanisms by which TAGLN2 confers treatment resistance for developing additional treatments for GBM. Additionally, active drug development efforts are also underway to target TAGLN2 for circumventing these therapeutic resistance mechanisms for effective GBM therapy. MATERIALS/METHODS RNAi-mediated TAGLN2 knockdown (KD) approach was employed to assess the functions of TAGLN2 in GBM patient-derived xenograft (PDX) cell lines. Series of in vitro functional assays were performed to assess the role of TAGLN2 in these cell lines. Cell proliferation, invasion ± RT and/or TMZ were assessed by MTS and Trans-well invasion assays. Subsequently, WB analysis of oncogenic signaling pathways was performed following Transgelin-2 KD. Co-IP assays and Biacore/SPR analyses were performed to study the binding affinity and kinetics for the interaction of PTEN with TAGLN2. Further, cells were intracranially implanted in nude mice to assess the role of TAGLN2 on tumor growth in vivo. RESULTS Conditional KD of TAGLN2 reduces cell proliferation, survival and invasive potential of GBM PDX cell lines. TAGLN2 KD also improved the sensitivity of these cells to both TMZ and radiation in vitro, as assessed by proliferation, survival, clonal expansion, and invasion. Histopathological studies of human GBM tumors and mouse xenograft tumors showed elevated expression of TAGLN2 in the peri-necrotic region of the tumors indicating that TAGLN2 protein level was upregulated by hypoxia. We also show that TAGLN2 is induced in hypoxic microenvironments with GBM PDX cell lines and its overexpression may enhance cellular resistance towards conventional therapy. Subsequently, we also show that hypoxia-induced TAGLN2 activates the PI3K/Akt oncogenic pathway through binding and inhibition of PTEN. Finally, in vivo data using an orthotopic xenograft mouse model shows reduction of tumor growth with knockdown of TAGLN2. CONCLUSION Our in vitro and in vivo xenograft studies suggest that TAGLN2 confers treatment resistance to GBM contributing to tumor recurrence. Altogether, TAGLN2 may serve as a potential therapeutically vulnerable target in GBM specifically through its role in cell survival and invasion.
Collapse
Affiliation(s)
- A Kumar
- Department of Radiation Oncology, Arthur G. James Hospital Ohio State Comprehensive Cancer Center, Columbus, OH
| | - P Rajasekera
- Department of Radiation Oncology, Arthur G. James Hospital/The Ohio State University Wexner Medical Center/Comprehensive Cancer Center, Columbus, OH
| | - V Becker
- 1Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| | - S Biehn
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - B Pérez-Soto
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J McElroy
- The Ohio State University, Center for Biostatistics, Department of Biomedical Informatics, Columbus, OH
| | - A Becker
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - B Johnson
- The Ohio State University, Columbus, OH
| | - T Cui
- The Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| | - E Sebastian
- Department of Radiation Oncology, Arthur G. James Hospital/The Ohio State University Wexner Medical Center/Comprehensive Cancer Center, Columbus, OH
| | - A Grosu
- German Cancer Consortium (DKTK), Partner Site Freiburg, Heidelberg, Germany
| | - S Lindert
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - E H Bell
- Administrative Director, Neuroscience Research Institute, Columbus, OH
| | - H Manring
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - J Haque
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| |
Collapse
|
13
|
Bazan J, Yaney A, Jhawar S, Beyer S, White J. Low Toxicity and Excellent Cosmesis with Highly Conformal Accelerated Partial Breast Irradiation Delivered Either Twice Daily or Every Other Day. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
14
|
Tong Z, Fleming J, Grozdic I, McElroy J, Beyer S, Fabian D, Becker A, Bell E, Mahler K, Popp I, Staszewski O, Manring H, Haque J, Grosu A, Chakravarti A. Therapeutic Potential of Small Molecule Inhibitors of TBK1 in Glioma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Perlow H, Ho C, Matsui J, Prasad R, Klamer B, Wang J, Damante M, Blakaj D, Beyer S, Lonser R, Hardesty D, Raval R, Prabhu R, Elder J, Palmer J. Pre-Operative vs. Post-Operative Fractionated Stereotactic Radiotherapy for Patients with Brain Metastases: A Multi-Institutional Analysis. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Yaney A, Fort M, Jhawar S, Beyer S, White J, Bazan J. Prospective Evaluation of Implementation of Esophageal Dose-Volume Constraints in Patients with Breast Cancer Undergoing Regional Nodal Irradiation. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
17
|
Kraus FBT, Topalov NE, Deuster E, Hysenaj I, Mayr D, Chelariu-Raicu A, Beyer S, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer. J Cancer Res Clin Oncol 2022; 149:2501-2511. [PMID: 35751684 PMCID: PMC10129941 DOI: 10.1007/s00432-022-04114-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 06/06/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE Despite recent advances in the treatment of ovarian cancer (OC), long-term remissions remain scarce. For a targeted approach, prognostic markers are indispensable for predicting survival and treatment response. Given their association with multiple hallmarks of cancer, histamine receptors (HR) are emerging as promising candidates. Here, we investigate their expression pattern and prognostic value in OC. METHODS Specimens of 156 epithelial OC patients were collected during cytoreductive surgery at the Department of Obstetrics and Gynecology, LMU, between 1990 and 2002 and combined in a tissue microarray. Immunohistochemical staining of the HR H1, H2, H3 and H4 was quantified by an immunoreactive score and linked with clinico-pathological data by Spearman's correlation. Via ROC curve analysis, optimal cut-off values for potential prognostic markers were defined. Overall survival (OS) was visualized in Kaplan-Maier curves and significances determined by log-rank testing. A Cox regression model was applied for multivariate analysis. RESULTS HR H3 and H4 expression was restricted to the cytosol of OC cells, while H1 was also present in the nucleus. A significant association between HR H1, H3 and H4 expression with several clinico-pathological parameters was revealed. In addition, HR H1 and H3 expression correlated positively, HR H4 expression negatively with OS. In addition, HR H3 was identified as independent prognostic marker for OS. HR H2 expression had no prognostic value. CONCLUSIONS HR H1, H3 and H4 could serve as potential predictors for OS of OC patients. Further research is warranted to elucidate their pathophysiologic role and their predictive and therapeutic potential in OC.
Collapse
Affiliation(s)
- Fabian B T Kraus
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
| | - Nicole E Topalov
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - E Deuster
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - I Hysenaj
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - D Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - A Chelariu-Raicu
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - S Beyer
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - T Kolben
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - A Burges
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - S Mahner
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - F Trillsch
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - U Jeschke
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - B Czogalla
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
18
|
Hahn L, Meister S, Mannewitz M, Beyer S, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T, Burges A. Gal-2 führt zu einer Erhöhung von H3K4me3 und H3K9ac
in Trophoblasten und in der Präeklampsie. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- L Hahn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie,
Klinikum der LMU München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
- Klinik für Frauenheilkunde und Geburtshilfe,
Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| |
Collapse
|
19
|
Müller L, Mitter S, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Jeschke U, Kessler M, Mahner S, Kolben T, Beyer S. Die Blutgruppenantigene SLeX, SLeA and Lewis Y als potenziell prognostische Faktoren im Endometrium- und Zervixkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Affiliation(s)
- L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
20
|
Topalov EN, Mayr D, Scherer C, Chelariu-Raicu A, Beyer S, Hester A, Kraus FBT, Zheng M, Kaltofen T, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Die funktionelle Rolle von Actin beta-like 2 in der Pathogenese des Ovarialkarzinoms und dessen prognostische Bedeutung für das Gesamtüberleben. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- E N Topalov
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - D Mayr
- Pathologisches Institut, Medizinische Fakultät, Universitätsklinikum der LMU, München
| | - C Scherer
- Medizinische Klinik und Poliklinik I, Universitätsklinikum der LMU, München
- DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), Munich Heart Alliance, Universitätsklinikum der LMU, München
| | - A Chelariu-Raicu
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - FBT Kraus
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Zheng
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kaltofen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
21
|
Dreyer EM, Meister S, Thomann M, Hahn L, Keilmann L, Beyer S, Mayer C, Prins G, Hermelink K, Hasbargen U, Mahner S, Kolben T. Einfluss der psychischen Belastung durch die COVID-19-Pandemie auf
das Auftreten von Wochenbettdepressionen und die Relevanz individueller
Stressbewältigungs-Strategien. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- E-M Dreyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - M Thomann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - L Hahn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - L Keilmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - C Mayer
- Fakultät für Psychologie, Universität
Würzburg
| | - G Prins
- Fakultät für Sozialwissenschaften, Universität
Augsburg
| | - K Hermelink
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| |
Collapse
|
22
|
Mitter S, Müller L, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Mahner S, Kessler M, Jeschke U, Kolben T, Beyer S. RIG-I – Expression als negativer prognostischer Faktor im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Pathologisches Institut, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
23
|
Kraus FBT, Topalov EN, Deuster E, Hysenaj I, Mayr D, Chelariu-Raicu A, Beyer S, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Expressionsmuster und prädiktives Potenzial der Histaminrezeptoren im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- FBT Kraus
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E N Topalov
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Deuster
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - I Hysenaj
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - D Mayr
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Chelariu-Raicu
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
24
|
Bedford E, Russo V, Dickman C, Li B, Jezierski A, Kim D, Jang J, Yin Y, Harrington D, Sharma R, De la Vega L, Willerth S, Salmeron L, Morgan J, Kieffer T, Beyer S, Mohamed T, Witek R, Getsios S, Wadsworth S. Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: PARTNERING TO ADVANCE THE DEVELOPMENT OF TISSUE THERAPEUTICS WITH MICROFLUIDIC 3D BIOPRINTING. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00412-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Raj R, Jhawar S, Stover D, Park K, Beyer S, Healy E, White J, Bazan J. De-Escalation of Radiation Therapy in Patients with cT1-T2 (< 3 cm) N0 HER2+ Breast Cancer Treated With Neoadjuvant Systemic Therapy With Pathologic Complete Response at the Time of Breast Conserving Surgery. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Dibs K, Palmer J, Olausson A, Bourekas E, Boulter D, Ayan A, Cochran E, Yildiz V, Grecula J, Arnett A, Raval R, Beyer S, Scharschmidt T, Elder J, Chakravarti A, Mendel E, Blakaj D. Circumferential Stereotactic Body Radiotherapy for Spine Metastasis: The Feasibility, Toxicity and Local Control. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Mladkova N, Smith T, Yildiz V, Healy E, Beyer S, DiCostanzo D, Jhawar S, Bazan J, White J. The Impact of Bioabsorbable 3D Fiducial Marker on Radiation Dosimetry and Cosmesis in Early Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Hatton C, Bailey T, Bradshaw J, Caton S, Flynn S, Gillooly A, Jahoda A, Maguire R, Marriott A, Mulhall P, Oloidi E, Taggart L, Todd S, Abbott D, Beyer S, Gore N, Heslop P, Scior K, Hastings RP. The willingness of UK adults with intellectual disabilities to take COVID-19 vaccines. J Intellect Disabil Res 2021; 65:949-961. [PMID: 34529314 PMCID: PMC8657332 DOI: 10.1111/jir.12884] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 07/29/2021] [Accepted: 08/29/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND Given the much greater COVID-19 mortality risk experienced by people with intellectual disabilities (ID), understanding the willingness of people with ID to take a COVID-19 vaccine is a major public health issue. METHOD In December 2020 to February 2021, across the United Kingdom, 621 adults with ID were interviewed remotely and 348 family carers or support workers of adults with ID with greater needs completed an online survey, including a question on willingness to take a COVID-19 vaccine if offered. RESULTS Eighty-seven per cent of interviewees with ID were willing to take a COVID-19 vaccine, with willingness associated with white ethnicity, having already had a flu vaccine, gaining information about COVID-19 from television but not from social media, and knowing COVID-19 social restrictions rules. A percentage of 81.7% of surveyed carers of adults with ID with greater needs reported that the person would be willing to take a COVID-19 vaccine, with willingness associated with white ethnicity, having a health condition of concern in the context of COVID-19, having had a flu vaccine, being close to someone who had died due to COVID-19, and having shielded at some point during the pandemic. CONCLUSIONS Reported willingness to take the COVID-19 vaccine is high among adults with ID in the United Kingdom, with factors associated with willingness having clear implications for public health policy and practice.
Collapse
Affiliation(s)
- C. Hatton
- Department of Social Care and Social WorkManchester Metropolitan UniversityManchesterUK
| | - T. Bailey
- Centre for Educational Development, Appraisal and ResearchUniversity of WarwickCoventryUK
| | | | - S. Caton
- Department of Social Care and Social WorkManchester Metropolitan UniversityManchesterUK
| | - S. Flynn
- Centre for Educational Development, Appraisal and ResearchUniversity of WarwickCoventryUK
| | - A. Gillooly
- Institute of Health and WellbeingUniversity of GlasgowGlasgowUK
| | - A. Jahoda
- Institute of Health and WellbeingUniversity of GlasgowGlasgowUK
| | - R. Maguire
- Institute of Health and WellbeingUniversity of GlasgowGlasgowUK
| | - A. Marriott
- National Development Team for InclusionBathUK
| | - P. Mulhall
- Institute of Nursing and Health ResearchUniversity of UlsterJordanstownUK
| | - E. Oloidi
- Unit for Development in Intellectual and Developmental DisabilitiesUniversity of South WalesPontypriddUK
| | - L. Taggart
- Institute of Nursing and Health ResearchUniversity of UlsterJordanstownUK
| | - S. Todd
- Unit for Development in Intellectual and Developmental DisabilitiesUniversity of South WalesPontypriddUK
| | - D. Abbott
- School for Policy StudiesUniversity of BristolBristolUK
| | - S. Beyer
- School of MedicineUniversity of CardiffCardiffUK
| | - N. Gore
- Tizard CentreUniversity of KentCanterburyUK
| | - P. Heslop
- School for Policy StudiesUniversity of BristolBristolUK
| | - K. Scior
- Division of Psychology and Language SciencesUniversity College LondonLondonUK
| | - R. P. Hastings
- Centre for Educational Development, Appraisal and ResearchUniversity of WarwickCoventryUK
- Centre for Developmental Psychiatry and PsychologyMonash UniversityMelbourneVICAustralia
| |
Collapse
|
29
|
Kumar A, Rajasekera P, Biehn S, Beyer S, McElroy J, Becker A, Johnson B, Cui T, Sebastian E, Grosu A, Lindert S, Bell E, Haque S, Chakravarti A. In-Silico Discovery of Novel Small-Molecule Inhibitors Targeting Transgelin-2-Actin Interaction Inhibits Proliferation, Invasion and Improves Chemo-Radiation Response in Human Glioblastoma. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Perlow H, Yang M, Siedow M, Boulter D, Fritz J, Miller E, Blakaj D, Zoller W, Cadieux C, Eiler D, Addington M, DiCostanzo D, Beyer S, Arnett A, Grecula J, Chakravarti A, Palmer J. 68(GA)DOTATATE PET-Based Radiation Volumes Demonstrate Increased Precision Compared to MRI Based Volumes for Meningioma Patients. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Velotti P, Rogier G, Zobel SB, Ciavolino E, Beyer S, Fonagy P. Preliminary data on the psychometric proprieties of the italian version of the reflective functioning questionnaire. Eur Psychiatry 2021. [PMCID: PMC9475880 DOI: 10.1192/j.eurpsy.2021.1362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Assessing mentalizing abilities is a complex issue. Only recently an instrument assessing mentalizing capacity as a whole, the Reflective Functioning Questionnaire (RFQ), has been developed. Objectives To reach the purpose of our study, we investigated the psychometric proprieties of the Italian version of the RFQ. Methods The study was conducted on a sample including a group of violent offenders and a group of community participants. All subjects fulfilled the RFQ, the Personality Inventory for DSM-5 (PID-5) and the Aggression Questionnaire (AQ). Results The theoretical model was defined and analysed by using Partial Least Squares–Path Modelling with high-order construct definition. Data showed good psychometric proprieties of the Italian version of the RFQ. Also, specific patterns of correlations were identified between the RFQ subscales and both PID-5 and AQ scores. Offenders significantly differed from controls only in relation to one subscale of the RFQ. Conclusions Data supported the factorial structure of the RFQ found in the original validation study. Results also support the existence of a second-order variable, mentalizing, resulting from the convergence of hypomentalizing and hypermentalizing.
Collapse
|
32
|
Patel S, Zhao S, Wei L, Li M, Bertino E, Presley C, Welliver M, Haglund K, Palmer J, Arnett A, Beyer S, Mende E, Elder J, Hardesty D, Shields P, Carbone D, Otterson G, Williams T, Owen D. P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Bazan J, Jhawar S, Healy E, Beyer S, White J. Does Intraoperative Radiation Therapy Result in Improved Overall Survival in Early-Stage Breast Cancer? An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
34
|
Bazan J, Kuhn K, Healy E, Jhawar S, Beyer S, DiCostanzo D, White J. PH-0601: Dosimetric Parameters Associated with Esophagitis in Regional Nodal Irradiation for Breast Cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00623-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Kumar A, Rajasekera P, Beyer S, McElroy J, Grosu A, Biehn S, Cui T, Becker A, Johnson B, Sebastian E, Lindert S, Bell E, Haque S, Chakravarti A. Pharmacological Targeting Of Transgelin-2 As A Novel Strategy Of Therapeutic Intervention In Glioblastoma. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
36
|
Mannewitz M, Beyer S, Meister S, Kolben T, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Kolben T. Impact of monocyte- and macrophage- derived CCL22 on endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T.M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
37
|
Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. PLA2G7/PAF-AH as protective factor and potential negative regulator of the Wnt signaling pathway in BRCA1 mutant ovarian cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- Y Liao
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Badmann
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kaltofen
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - D Mayr
- LMU München, Institut für Pathologie
| | | | - E Deuster
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - M Mannewitz
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | | | - T Kolben
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Burges
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe
| | - F Trillsch
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - B Czogalla
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
38
|
Hahn L, Beyer S, Kolben T, Schmoeckel E, Mayr D, Anz D, Kuhn C, Vattai A, Hester A, Corradini S, Hasbargen U, Mahner S, Jeschke U, Meister S, Kolben T. Verminderte Rekrutierung regulatorischer T-Zellen bei erhöhter CCL22-Expression in der Präeklampsie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Hahn
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T.M Kolben
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - E Schmoeckel
- Klinikum der LMU München, Pathologisches Institut
| | - D Mayr
- Klinikum der LMU München, Pathologisches Institut
| | - D Anz
- Klinikum der LMU München, Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology
| | - C Kuhn
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Vattai
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Corradini
- Klinikum der LMU München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie
| | - U Hasbargen
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Meister
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
39
|
Kellner I, Beyer S, Hasbargen U, Mahner S, Hester A, Vattai A, Jeschke U, Corradini S, Kolben T, Kolben T, Meister S. Die Immunreaktion im Abortgeschehen – Interaktion von Immunzellen untereinander und mit der Umgebung im Bereich der Plazenta und der Zusammenhang mit dezidualen Mikrothrombosen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- I.M Kellner
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Hasbargen
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Vattai
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Corradini
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie
| | - T.M Kolben
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Meister
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | | |
Collapse
|
40
|
Badmann S, Mayr D, Schmoeckel E, Hester A, Kolben T, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. AKR1C1/2 inhibition by MPA resensitizes platinum resistant ovarian cancer towards platinum-based chemotherapy. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Badmann
- LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - D Mayr
- LMU München, Institut für Pathologie
| | | | - A Hester
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Burges
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe
| | - F Trillsch
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - B Czogalla
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
41
|
Wehrmann M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Mahner S, Jeschke U, Kolben T. Galectin-8 and -9 as prognostic factors for cervical cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
42
|
Kremer N, Vattai A, Schmöckel E, Meister S, Beyer S, Czogalla B, Fürst S, Mahner S, Corradini S, Jeschke U, Kolben T, Kolben T. Rolle der Makrophagendifferenzierung und -interaktion mit regulatorischen T-Zellen bei der Progression und Regression der HPV-induzierten Zervixdysplasie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- N Kremer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - A.S Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - E Schmöckel
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Fürst
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Corradini
- Klinik für Strahlentherapie, Klinikum der Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
- Klinik und für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
43
|
Wehrmann M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Mahner S, Jeschke U, Beyer S. Gal-8, Gal-9, Histone H3-Acetyl-K9, Histone H3-Trimethyl-K4 and Glucocorticoid Receptor as possible prognostic markers in endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
44
|
Meister S, Hahn L, Beyer S, Kolben T, Schmoeckel E, Mayr D, Vattai A, Hester A, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T. Die Rolle epigenetischer Modifikationen in der Präeklampsie im Zusammenhang mit PPARγ (Peroxisom-Proliferator-aktivierter Rezeptor-γ) und Galectin-2. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Meister
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - L Hahn
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T.M Kolben
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - E Schmoeckel
- Ludwig-Maximilians-Universität München, Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - D Mayr
- Ludwig-Maximilians-Universität München, Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - A Vattai
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - A Hester
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Corradini
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie
| | - U Hasbargen
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Jeschke
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
45
|
Meister S, Kolben T, Beyer S, Hutter S, Kuhn C, Mayr D, Solano M, Jegen M, Hasbargen U, Mahner S, Arck P, Jeschke U. Geschlechtsspezifische epigenetische Aktivierung von Genen bei intrauteriner Wachstumsretardierung (IUGR). Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Meister
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Kolben
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Beyer
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Hutter
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - C Kuhn
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - D Mayr
- Ludwig-Maximilians-Universität München, Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - M.E Solano
- Uniklinikum Hamburg-Eppendorf, Geburtshilfe und Gynäkologie
| | - M Jegen
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - U Hasbargen
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - P Arck
- Uniklinikum Hamburg-Eppendorf, Geburtshilfe und Gynäkologie
| | - U Jeschke
- Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
46
|
Beyer S, Fangfang C, Meister S, Czogalla B, Kolben TM, Hester A, Burges A, Trillsch F, Schmoeckel E, Mayr D, Mayerhofer A, Mahner S, Jeschke U, Kolben T. Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - C Fangfang
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Mayerhofer
- Biomedizinisches Zentrum München (BMC), Zellbioloige, Anatomie III, LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
47
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression of H3K4me3 and H3K9ac in breast cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
48
|
Mannewitz M, Kolben T, Meister S, Kolben T, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Corradini S, Czogalla B, Mahner S, Jeschke U, Beyer S. Regulatory T-cells as a potential target to overcome immune evasion in endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T.M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
49
|
Schulze M, Beyer S, Beyer F, Bortfeldt R, Riesenbeck A, Leiding C, Jung M, Kleve-Feld M. Relationship between pubertal testicular ultrasonographic evaluation and future reproductive performance potential in Piétrain boars. Theriogenology 2020; 158:58-65. [PMID: 32932185 DOI: 10.1016/j.theriogenology.2020.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 08/31/2020] [Accepted: 09/02/2020] [Indexed: 01/17/2023]
Abstract
New ways of predicting sperm quality and output performance in young artificial insemination (AI) boars are important for breeding companies to ensure that the pubertal boars delivered to the AI studs have a high chance of meeting minimum quality standards to be used for insemination and therewith dissemination of desirable characteristics. The aim of the current study was to characterize the testicular development of 218 pubertal Piétrain boars (Line 408, Pig Improvement Company) to identify traits with predictable characteristics relative to their sperm quality as an adult AI boar. Scrotum, testes and epididymis were examined ultrasonographically at day (d) 100 (on-test) and 170 (off-test) followed by a computer-assisted grayscale analysis (GSA). Over the test period, paired testicular volume increased 7.3-fold from 22.7 ± 10.8 cm3 to 166.6 ± 62.2 cm3. The right testis was significantly (P = 0.014) larger than the left one at the off-test. Based on the sperm quality (ejaculate volume, sperm concentration, total sperm number, morphologically abnormal sperm and total sperm motility at day 3 of semen storage), 82.11% (n = 179) of the boars were classified as "productive" boars. These boars had a significantly (P = 0.039) larger paired testicular volume than "non-productive" boars (45.9 ± 19.9 cm3vs. 38.5 ± 12.6 cm3) at the on-test. For the right testis at on-test, significant differences for the standard deviation of mean gray value (P = 0.022), area under the curve (P = 0.004) and mean gradient value (GRAD, P = 0.030) regarding the future sperm production capacity (SPC) were shown. At off-test, there was a significant difference for minimum gray value (MIN GV, P = 0.003) and mean gray value (P = 0.001) related to SPC. To find SPC related cut-off values for GSA data, a two segmental non-linear regression analysis was carried out indicating breakpoints for GRAD ≥12 and MIN GV ≥ 40 for boars with low SPC. Off-test boars with MIN GV ≥ 40 showed a 2.4 higher risk to display low SPC (Odds ratio = 2.4 [1.1, 5.4]; P = 0.024). The results may enable breeding companies to include new sperm quality associated traits in their boar testing and selection programs.
Collapse
Affiliation(s)
- M Schulze
- Institute for Reproduction of Farm Animals Schönow, Bernauer Allee 10, D-16321, Bernau, Germany.
| | - S Beyer
- Institute for Reproduction of Farm Animals Schönow, Bernauer Allee 10, D-16321, Bernau, Germany
| | - F Beyer
- Institute for Reproduction of Farm Animals Schönow, Bernauer Allee 10, D-16321, Bernau, Germany
| | - R Bortfeldt
- Institute for Reproduction of Farm Animals Schönow, Bernauer Allee 10, D-16321, Bernau, Germany
| | - A Riesenbeck
- Genossenschaft Zur Förderung der Schweinehaltung, Zum Pöpping 29, D-59387, Ascheberg, Germany
| | - C Leiding
- Besamungsverein Neustadt a. d. Aisch e. V., Karl-Eibl-Str. 17-27, D-91413, Neustadt a. d. Aisch, Germany
| | - M Jung
- Institute for Reproduction of Farm Animals Schönow, Bernauer Allee 10, D-16321, Bernau, Germany
| | - M Kleve-Feld
- Pig Improvement Company, 100 Bluegrass Commons Blvd. Ste 2200, Hendersonville, TN, 37075, United States
| |
Collapse
|
50
|
Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. 851P PLA2G7/PAF-AH as protective factor and potential negative regulator of the Wnt signaling pathway in BRCA1 mutant ovarian cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|